Skip to main content
Clinical Trials/NCT04885205
NCT04885205CompletedNot Applicable

Use of Cognitive Behavioral Therapy for Insomnia in Individuals With a Concussion

University of Kansas Medical Center1 site in 1 country40 target enrollmentStarted: April 30, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
40
Locations
1
Primary Endpoint
change in Insomnia Severity Index

Study Overview

Brief Summary

Sleep disturbances have been shown to contribute to poorer recovery from a concussion. Furthermore, sleep disturbances have been associated with more frequent and severe post-concussion symptoms including headache, vertigo, anxiety, depression, and decreased short term memory reducing quality of life and productivity at work or school. Additionally, recent research indicates that individuals with a concussion who have poor sleep quality have increased levels of Neurofilament light (NfL) and tau biomarkers indicating that there may still be axonal damage after weeks or months after the initial concussion injury. Post-concussion symptoms have been associated with higher levels of these biomarkers and there has been a report of higher levels of NfL and tau years following a concussion event. Cognitive behavioral therapy for insomnia (CBT-I) is an effective treatment for insomnia yet it remains unclear if this treatment method is effective in improving sleep outcomes, reducing concomitant post-concussion symptoms, and biomarkers of neural injury/risk in individuals post- concussion. The central hypothesis for this project is treating sleep disturbances will yield a clinically relevant reduction in concomitant post-concussion symptoms. The objective for the proposed study is to determine if CBT-I will reduce insomnia symptoms and improve concomitant post-concussion symptoms in individuals after concussion and if symptom improvements are maintained at 6-weeks and 12-weeks after CBT-I intervention.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 64 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Aged 18 to 64 years old
  • •At least 4 weeks since concussion injury
  • •Self-report difficulty falling asleep, maintaining sleep, or waking up too early at least 3 nights per week since injury
  • •Score ≥10 on the Insomnia Severity Index to indicate clinical insomnia.
  • •Score ≥25 on the Mini-Mental State Examination (MMSE) questionnaire

Exclusion Criteria

  • •Known untreated sleep disorder (such as sleep apnea, restless leg syndrome, circadian rhythm disorder, hypersomnia, parasomnias)
  • •Increased risk obstructive sleep apnea (STOP BANG Score ≥3)
  • •Increased risk of restless leg syndrome on RLS-Diagnosis Index
  • •Increased risk of circadian rhythm sleep-wake disorder (respond "Yes" to all circadian rhythm questions).
  • •Increased risk of parasomnia (Respond "Yes" to all questions for night mere disorder OR respond "Yes" to all REM sleep arousal disorder: Sleep walking questions, OR responds " Yes" to all REM sleep arousal disorder: Sleep Terrors questions, OR respond "Yes" to all REM sleep behavior disorder questions.)
  • •Active abuse or history (up to 2 years) of alcohol/ drug dependence as defined by the DSM-V criteria
  • •Severe mental illness such as schizophrenia or bipolar disorder
  • •Score of > 29 on the Beck Depression Inventory or indication of suicidality (response of "2" or "3"to item 9)
  • •History of diagnosed nervous system disorder other than concussion (such as multiple sclerosis, Parkinson's Disease, Stroke)
  • •Currently works nightshift

Arms & Interventions

CBT-I Initial Group

Experimental

The CBT-I Initial Group will start the CBT-I intervention immediately following baseline assessments. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.

Intervention: cognitive behavioral therapy for insomnia (CBT-I) (Behavioral)

Wait List Group

Active Comparator

The WL will wait 6 weeks before starting the CBT-I intervention. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.

Intervention: cognitive behavioral therapy for insomnia (CBT-I) (Behavioral)

Outcomes

Primary Outcomes

change in Insomnia Severity Index

Time Frame: baseline to 21 weeks

7 questions each rated on a 0-4 scale. The range of scores on the ISI is 0-28

change in Post-Concussion Symptom Scale

Time Frame: baseline to 21 weeks

Severity of 22 concussion-related symptoms are assessed by a Likert scale 0-6. Participants will rate their symptoms from a "0" or no symptom to "6" extreme symptom. A score of 132 is the maximum someone can have indicating all symptoms are severe. 2. The number of post-concussion symptoms will be assessed by counting the number of symptoms that the participant identified as having a severity of "1" or higher on the PCSS. A score of a "1" indicates that the symptom is mild, but still noticeable.

change in Beck Anxiety Inventory

Time Frame: baseline to 21 weeks

The tool consists of 21 items that are scored on a Likert scale of 1-3. Scores range from minimal anxiety (0-7), mild anxiety (8-15) moderate anxiety (16-25) and severe anxiety (\<30).

change in PSQI

Time Frame: baseline to 21 weeks

Scores range from 0-21 with a higher score indicating a lower quality of sleep

change in Beck Depression Inventory

Time Frame: baseline to 21 weeks

21 item questionnaire used to assess the severity of depression. Scores range from 1 to greater than 40.

Secondary Outcomes

  • change in plasma pTau181(baseline to 21 weeks)
  • change in Sleep Self-Efficacy(baseline to 21 weeks)
  • change in RU-SATED questionnaire(baseline to 21 weeks)
  • change in plasma neurofilament light (NfL)(baseline to 21 weeks)
  • change in Dysfunctional Beliefs About Sleep (DBAS)(baseline to 21 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials